Literature DB >> 23524581

BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.

M Sung1, P Giannakakou1.   

Abstract

The taxanes are effective microtubule-stabilizing chemotherapy drugs used in the treatment of various solid tumors. However, the emergence of drug resistance hampers their clinical efficacy. The molecular basis of clinical taxane resistance remains poorly understood. Breast cancer 1, early onset gene, BRCA1, is a tumor-suppressor gene, whose expression has been correlated with taxane sensitivity in many solid tumors including non-small cell lung cancer. However, the molecular mechanism underlying the relationship between BRCA1 (B1) expression and taxane activity remains unclear. To this end, we created a stable B1 knockdown A549 cell line (B1-KD) to investigate B1's role in microtubule biology and response to taxane treatment. We show that B1-KD rendered A549 cells resistant to paclitaxel (PTX), phenocopying clinical studies showing that low B1 expression correlated with taxane resistance. As previously reported, we show that loss of B1 enhanced centrosomal γ-tubulin localization and microtubule nucleation. Interestingly, we found that the B1-KD cells exhibited increased microtubule dynamics as compared with parental A549 cells, as assessed by live-cell confocal microscopy using enhanced green fluorescent protein-tagged α-tubulin or EB1 protein. In addition, we showed that loss of B1 impairs the ability of PTX to induce microtubule polymerization using immunofluorescence microscopy and a cell-based tubulin polymerization assay. Furthermore, B1-KD cells exhibited significantly lower intracellular binding of a fluorescently labeled PTX to microtubules. Recent studies have shown that PTX-stabilized microtubules serves as a scaffold for pro-caspase-8 binding and induction of apoptosis downstream of induced-proximity activation of caspase-8. Here we show that loss of B1 reduces the association of pro-caspase-8 with microtubules and subsequently leads to impaired PTX-induced activation of apoptosis. Taken together, our data show that B1 regulates indirectly endogenous microtubule dynamics and stability while its loss leads to microtubules that are more dynamic and less susceptible to PTX-induced stabilization conferring taxane resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524581      PMCID: PMC3865028          DOI: 10.1038/onc.2013.85

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin.

Authors:  A M Minotti; S B Barlow; F Cabral
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

Review 2.  Mitosis is not a key target of microtubule agents in patient tumors.

Authors:  Edina Komlodi-Pasztor; Dan Sackett; Julia Wilkerson; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

3.  Reconstitution of a microtubule plus-end tracking system in vitro.

Authors:  Peter Bieling; Liedewij Laan; Henry Schek; E Laura Munteanu; Linda Sandblad; Marileen Dogterom; Damian Brunner; Thomas Surrey
Journal:  Nature       Date:  2007-12-02       Impact factor: 49.962

4.  Axon injury and stress trigger a microtubule-based neuroprotective pathway.

Authors:  Li Chen; Michelle C Stone; Juan Tao; Melissa M Rolls
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

5.  A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

Authors:  K Roszkowski; A Pluzanska; M Krzakowski; A P Smith; E Saigi; U Aasebo; A Parisi; N Pham Tran; R Olivares; J Berille
Journal:  Lung Cancer       Date:  2000-03       Impact factor: 5.705

6.  Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling.

Authors:  Guoqiang Xu; Jeremy S Paige; Samie R Jaffrey
Journal:  Nat Biotechnol       Date:  2010-07-18       Impact factor: 54.908

7.  Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics.

Authors:  Paraskevi Giannakakou; Michel Nakano; Kyriacos C Nicolaou; Aurora O'Brate; Jian Yu; Mikhail V Blagosklonny; Urs F Greber; Tito Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

10.  Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression.

Authors:  Marisa Carbonaro; Aurora O'Brate; Paraskevi Giannakakou
Journal:  J Cell Biol       Date:  2011-01-10       Impact factor: 10.539

View more
  16 in total

1.  Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

Authors:  Nicholas W Bateman; Elizabeth Jaworski; Wei Ao; Guisong Wang; Tracy Litzi; Elizabeth Dubil; Charlotte Marcus; Kelly A Conrads; Pang-ning Teng; Brian L Hood; Neil T Phippen; Lisa A Vasicek; William P McGuire; Keren Paz; David Sidransky; Chad A Hamilton; G Larry Maxwell; Kathleen M Darcy; Thomas P Conrads
Journal:  J Proteome Res       Date:  2015-03-19       Impact factor: 4.466

2.  Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

Authors:  Renée de Leeuw; Lisa D Berman-Booty; Matthew J Schiewer; Stephen J Ciment; Robert B Den; Adam P Dicker; William K Kelly; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2015-02-15       Impact factor: 12.531

3.  Mechanisms of resistance to cabazitaxel.

Authors:  George E Duran; Yan C Wang; E Brian Francisco; John C Rose; Francisco J Martinez; John Coller; Diana Brassard; Patricia Vrignaud; Branimir I Sikic
Journal:  Mol Cancer Ther       Date:  2014-11-21       Impact factor: 6.261

Review 4.  Mechanisms of cancer cell death induction by paclitaxel: an updated review.

Authors:  Shuang Zhao; Yufei Tang; Ruohan Wang; Masoud Najafi
Journal:  Apoptosis       Date:  2022-07-18       Impact factor: 5.561

Review 5.  Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy.

Authors:  Jia-Hui Xu; Shi-Lian Hu; Guo-Dong Shen; Gan Shen
Journal:  Cancer Cell Int       Date:  2016-02-20       Impact factor: 5.722

6.  The Effect of SIN1 and Microtubules on Insulin Induced PKC ζ Activation.

Authors:  Xiang Yingying; Wang Caijuan; Yue Yenan; Tang Yuqin; Cai Xueqin; Wu Zhongming
Journal:  Med Sci Monit       Date:  2017-07-28

Review 7.  Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.

Authors:  Robert L Hollis; Michael Churchman; Charlie Gourley
Journal:  Onco Targets Ther       Date:  2017-05-11       Impact factor: 4.147

8.  PRUNE is crucial for normal brain development and mutated in microcephaly with neurodevelopmental impairment.

Authors:  Massimo Zollo; Mustafa Ahmed; Veronica Ferrucci; Vincenzo Salpietro; Fatemeh Asadzadeh; Marianeve Carotenuto; Reza Maroofian; Ahmed Al-Amri; Royana Singh; Iolanda Scognamiglio; Majid Mojarrad; Luca Musella; Angela Duilio; Angela Di Somma; Ender Karaca; Anna Rajab; Aisha Al-Khayat; Tribhuvan Mohan Mohapatra; Atieh Eslahi; Farah Ashrafzadeh; Lettie E Rawlins; Rajniti Prasad; Rashmi Gupta; Preeti Kumari; Mona Srivastava; Flora Cozzolino; Sunil Kumar Rai; Maria Monti; Gaurav V Harlalka; Michael A Simpson; Philip Rich; Fatema Al-Salmi; Michael A Patton; Barry A Chioza; Stephanie Efthymiou; Francesca Granata; Gabriella Di Rosa; Sarah Wiethoff; Eugenia Borgione; Carmela Scuderi; Kshitij Mankad; Michael G Hanna; Piero Pucci; Henry Houlden; James R Lupski; Andrew H Crosby; Emma L Baple
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

Review 9.  A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: a strange case of Dr. Jekyll and Mr. Hyde.

Authors:  Jolie Kiemlian Kwee
Journal:  Biomed Res Int       Date:  2014-04-03       Impact factor: 3.411

10.  Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability.

Authors:  Makoto Iimori; Sugiko Watanabe; Shinichi Kiyonari; Kazuaki Matsuoka; Ryo Sakasai; Hiroshi Saeki; Eiji Oki; Hiroyuki Kitao; Yoshihiko Maehara
Journal:  Nat Commun       Date:  2016-03-31       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.